two
molecular
assay
compar
realtim
rtpcr
viral
cultur
simultan
detect
common
virus
respiratori
sampl
multiplex
ligationdepend
probe
amplif
mlpa
dual
prime
oligonucleotid
system
dpo
addit
posit
detect
mlpa
dpo
identifi
use
two
differ
automat
electrophoresi
system
panel
cultureposit
neg
sampl
test
molecular
assay
presenc
influenza
b
viru
respiratori
syncyti
viru
human
metapneumoviru
rhinoviru
coronavirus
parainfluenza
virus
adenoviru
one
hundr
twentynin
sampl
posit
detect
least
one
method
sixtynin
sampl
posit
cell
cultur
exclud
human
metapneumoviru
coronavirus
rtpcr
mlpa
dpo
mlpa
yield
result
one
attempt
sampl
includ
sampl
repeat
dpo
assay
due
inconclus
result
mlpa
assay
perform
well
combin
either
electrophoresi
system
perform
dpo
assay
influenc
electrophoresi
system
molecular
assay
compar
realtim
rtpcr
sensit
viral
cultur
detect
dual
infect
easili
result
obtain
within
day
pneumonia
seriou
ill
signific
morbid
mortal
rate
wide
varieti
bacteria
virus
held
respons
caus
pneumonia
children
well
adult
although
patient
etiolog
establish
johnston
et
al
michelow
et
al
sinc
sign
symptom
present
rare
point
specif
pathogen
usual
start
empir
therapi
aim
bacteri
pathogen
consid
frequenc
viral
etiolog
antibacteri
therapi
often
employ
inadequ
unnecessarili
comparison
convent
detect
techniqu
multiplex
realtim
pcr
shown
sensit
specif
yield
result
within
h
bonzel
et
al
templeton
et
al
enabl
direct
detect
virus
difficult
cultur
falsey
et
al
fouchier
et
al
mahoni
consequ
result
nucleic
acid
amplif
test
may
contribut
time
treatment
decis
studi
two
commerci
molecular
assay
design
simultan
detect
common
virus
varieti
respiratori
sampl
compar
realtim
rtpcr
viral
cultur
multiplex
ligationdepend
probe
amplif
mlpa
dual
prime
oligonucleotid
system
dpo
mlpa
techniqu
employ
two
probe
ligat
presenc
targetspecif
complementari
sequenc
probe
consist
targetspecif
sequenc
common
primer
sequenc
stretch
nucleotid
allow
specif
detect
base
length
differ
reijan
et
al
dpo
techniqu
employ
targetspecif
primer
doubl
normal
oligo
length
contain
polydeoxyinosin
linker
gain
specif
sensit
multiplex
detect
drew
et
al
addit
posit
detect
mlpa
dpo
assay
identifi
two
differ
automat
capillari
electrophoresi
detect
system
prior
valid
use
patient
sampl
pilot
studi
carri
use
dilut
viru
strain
confirm
specif
detect
includ
molecular
assay
except
human
corona
viru
viral
target
includ
molecular
assay
list
tabl
valid
panel
consist
viral
cell
cultureposit
cultureneg
respiratori
sampl
eightyseven
sampl
posit
cultur
detect
one
viral
target
posit
rtpcr
result
coronaviru
hmpv
submit
cultureneg
sampl
match
base
sampl
type
age
patient
rang
week
year
old
median
age
month
sampl
collect
sever
differ
year
ensur
strain
variabl
panel
respiratori
sampl
consist
bronchioalveolar
lavag
n
sputa
n
nasopharyng
lavag
n
nasopharyng
n
throat
n
swab
store
c
prior
nucleic
acid
extract
sampl
submit
molecular
assay
without
knowledg
cell
cultur
result
obtain
prior
storag
c
respiratori
sampl
cultur
c
use
four
differ
cell
line
coverslip
hel
human
embryon
lung
fibroblast
vero
african
green
monkey
larynxcarcinoma
rhesu
monkey
kidney
use
minimum
essenti
medium
mem
mm
lglutamin
earl
bss
adjust
gl
sodium
bicarbon
fetal
bovin
serum
addit
penicillin
ul
streptomycin
gl
amphotericin
b
mgl
cultur
examin
daili
cytopath
effect
cpe
addit
cultur
examin
day
use
immunofluoresc
antibodi
common
respiratori
pathogen
includ
rsv
adenoviru
influenza
viru
b
parainfluenza
viru
dfa
respiratori
viru
screeningid
kit
itk
diagnost
bv
uithoorn
netherland
dilut
seri
cultur
rsv
influenza
viru
b
submit
mlpa
dpo
realtim
rtpcr
tcid
experi
cell
rsv
cell
influenza
viru
determin
infect
dose
cell
cultur
dilut
prepar
mainten
cultur
medium
l
dilut
use
cultur
well
well
nucleic
acid
extract
eight
dilut
seri
per
viru
use
posit
check
use
cpe
day
extract
total
nucleic
acid
perform
nuclisen
easymag
boxtel
netherland
protocol
use
specif
board
lysi
l
silica
mix
mix
l
sampl
l
salin
use
extract
mlpa
protocol
requir
intern
control
ad
lysi
extract
mixtur
nucleic
acid
extract
elut
l
elut
buffer
store
c
molecular
test
mlpa
respifind
dc
twostep
kit
pathofind
maastricht
netherland
conduct
accord
manufactur
protocol
use
abi
thermocycl
appli
biosystem
foster
citi
ca
usa
short
l
nucleic
acid
extract
ad
l
preamplif
mix
second
hybridis
step
carri
l
dilut
preamplif
product
l
fresh
hybridis
reaction
mix
ligat
final
pcr
carri
simultan
third
reaction
mix
consist
l
mix
l
hybridis
product
pcr
product
store
c
electrophoresi
total
mlpa
protocol
includ
extract
perform
approxim
h
dpo
assay
seeplex
detect
kit
seegen
rockvil
md
usa
conduct
accord
manufactur
protocol
use
abi
thermocycl
short
revers
transcript
step
carri
l
rt
reaction
mix
initi
denatur
step
l
reaction
mix
l
nucleic
acid
extract
follow
pcr
carri
two
reaction
mix
consist
either
l
rv
mix
b
l
cdna
pcr
product
store
c
electrophoresi
total
dpo
protocol
includ
extract
complet
approxim
h
sampl
includ
valid
panel
submit
twostep
realtim
rtpcr
rtpcr
carri
sim
tabl
reaction
analys
use
two
microcapillari
electrophoresi
system
agil
agil
technolog
santa
clara
ca
usa
experion
biorad
laboratori
hercul
ca
usa
prescrib
respect
manufactur
input
system
l
amplicon
result
examin
two
differ
technician
exclud
interpret
differ
identif
obtain
agil
use
calcul
defin
true
posit
sampl
yield
posit
viral
detect
one
method
cultur
dpo
mlpa
realtim
rtpcr
sampl
remain
neg
method
consid
true
neg
posit
result
obtain
one
method
consid
unconfirm
falseposit
calcul
perform
use
microsoft
excel
version
tcid
cutoff
rsv
cultur
determin
dilut
cpe
tcid
influenza
viru
type
b
cpe
highest
dilut
yield
specif
reaction
rsv
mlpa
dpo
highest
dilut
yield
specif
reaction
influenza
viru
mlpa
assay
dpo
assay
result
simplex
realtim
rtpcr
assay
ident
mlpa
actual
input
molecular
assay
lower
cultur
extract
protocol
result
show
analyt
sensit
rsv
detect
slightli
greater
cultur
compar
molecular
method
greatest
sensit
influenza
viru
obtain
mlpa
rtpcr
lowest
dpo
assay
specif
detect
includ
two
molecular
assay
valid
use
nucleic
acid
extract
cultur
viru
strain
viru
strain
identifi
success
specif
confirm
total
collect
sampl
use
valid
panel
five
sampl
exclud
one
sampl
inhibit
repeatedli
mlpa
four
sampl
insuffici
volum
left
perform
test
total
sampl
includ
comparison
sampl
posit
one
two
viral
target
includ
unconfirm
fals
detect
sixtynin
sampl
cell
cultureposit
sampl
rtpcr
posit
sampl
yield
posit
mlpa
result
sampl
found
posit
dpo
tabl
perform
per
method
detect
rate
summaris
tabl
viru
specif
detect
summaris
per
method
tabl
show
number
detect
exce
amount
posit
sampl
due
mix
infect
mlpa
result
obtain
detect
system
ident
viru
detect
except
inhibit
sampl
could
identifi
singl
attempt
interpret
differ
technician
one
sampl
inhibit
repeatedli
mlpa
therefor
exclud
dpo
agil
perform
better
experion
agil
show
clearer
differ
background
signal
specif
signal
agil
enabl
clear
interpret
sampl
one
attempt
experion
yield
clear
interpret
sampl
repeat
electrophoresi
result
six
sampl
one
agil
five
experion
two
technician
disagre
interpret
therefor
complet
dpo
protocol
repeat
six
sampl
experion
run
hamper
electrophoresi
run
repeat
addit
six
sampl
inhibit
use
dpo
three
use
mlpa
calcul
amplicon
size
differ
slightli
agil
experion
electrophoresi
system
amplicon
size
calcul
base
marker
includ
kit
reagent
greater
perform
agil
viru
detect
mlpa
dpo
mention
result
base
combin
agil
electrophoresi
sampl
test
simplex
realtim
rtpcr
confirm
result
comparison
posit
viral
detect
found
one
method
unconfirm
fals
detect
list
bracket
tabl
specif
rtpcr
repeat
seven
detect
could
confirm
includ
six
mlpa
detect
three
rhinoviru
two
coronaviru
one
adenoviru
detect
one
dpo
detect
rhinoviru
detect
seven
high
threshold
cycl
ct
valu
rang
ct
ct
mix
infect
found
initi
detect
one
method
mlpa
detect
dual
infect
confirm
rtpcr
detect
dual
infect
viral
cell
cultur
detect
one
dual
infect
dpo
detect
dual
infect
confirm
tabl
viru
detect
involv
mix
infect
distribut
virus
shown
tabl
perform
two
commerci
molecular
detect
assay
mlpa
dpo
compar
use
panel
respiratori
sampl
molecular
assay
yield
compar
sensit
rtpcr
significantli
greater
sensit
respiratori
specimen
viral
cultur
exclud
hmpv
coronavirus
cell
cultur
undertaken
accord
earlier
public
kim
et
al
reijan
et
al
yoo
et
al
mlpa
assay
appear
greater
sensit
viral
target
compar
dpo
similar
sensit
compar
realtim
rtpcr
overal
specif
dpo
assay
appear
greater
compar
mlpa
howev
sensit
mlpa
decreas
specif
due
number
falseposit
might
well
socal
falseposit
detect
fact
accur
detect
shown
seven
addit
detect
confirm
rtpcr
discrep
test
low
viral
load
sampl
confirm
high
ct
valu
obtain
repeat
extract
rtpcr
comparison
analyt
sensit
sensit
obtain
respiratori
sampl
influenza
viru
type
b
show
similar
differ
mlpa
dpo
assay
differ
sensit
rsv
less
obviou
greater
detect
rate
molecular
assay
explain
greater
potenti
detect
coinfect
two
virus
chosen
tcid
sensit
comparison
differ
sensit
observ
valid
panel
sensit
dpo
assay
might
enhanc
lower
amount
intern
control
ic
strength
ic
signal
compar
specif
target
signal
might
due
competit
amplif
typespecif
viral
detect
per
molecular
assay
tabl
could
differenti
except
parainfluenza
viru
type
detect
cluster
mlpa
coronaviru
differenti
dpo
assay
sampl
panel
use
coronaviru
present
dpo
detect
identifi
mlpa
least
one
parainfluenza
detect
mlpa
identifi
rtpcr
two
case
viru
isol
cultur
influenza
b
viru
parainfluenza
detect
molecular
assay
virus
found
patient
dual
infect
parainfluenza
combin
enteroviru
neonat
influenza
b
viru
herp
simplex
viru
bronchoalveolar
fluid
patient
found
specif
test
cover
slip
amount
viru
origin
clinic
sampl
probabl
low
durat
storag
handl
might
influenc
qualiti
sampl
although
laboratori
contamin
might
plausibl
explan
well
molecular
assay
compar
sever
aspect
multiplex
format
target
identif
base
length
differ
amplicon
common
respiratori
virus
includ
howev
dpo
assay
faster
easier
perform
mlpa
consist
handson
step
hand
mlpa
sever
advantag
dpo
first
con
tabl
posit
detect
per
target
organ
squar
bracket
addit
possibl
posit
unconfirm
falseposit
last
column
detect
mix
infect
posit
detect
consid
therefor
percentag
calcul
versu
posit
total
sampl
includ
comparison
tain
intern
control
ad
prior
extract
therefor
control
extract
well
inhibit
dpo
ad
extract
second
differ
perform
electrophoresi
system
appar
dpo
assay
sampl
repeat
experion
run
inhibit
sampl
taken
account
overal
peak
sharper
seem
pronounc
experion
compar
obtain
agil
howev
result
falseposit
andor
fals
target
identif
due
background
signal
mlpa
show
virtual
background
problem
encount
mlpa
result
two
electrophoresi
system
ident
mlpa
assay
assay
unabl
produc
quantit
result
wherea
realtim
rtpcr
estim
semiquantit
result
per
sampl
howev
assay
rel
peakheight
provid
inform
viral
load
compar
intern
control
multipl
viru
detect
anoth
drawback
assay
fact
sampl
cup
open
format
cdna
therefor
risk
crosscontamin
exist
suffici
number
control
sampl
includ
molecular
assay
reveal
high
frequenc
doubl
infect
tabl
specif
coronavirus
rsv
rhinoviru
frequent
detect
mix
infect
viral
cultur
one
dual
infect
identifi
probabl
due
overgrowth
faster
grow
viru
identifi
infect
agent
follow
posit
identif
cultur
usual
examin
dual
infect
could
thu
miss
easili
virus
involv
commonli
dual
infect
coronaviru
detect
easili
cultur
sever
studi
point
sever
clinic
cours
associ
dual
infect
caracciolo
et
al
johnston
et
al
et
al
therefor
import
sensit
test
abl
identifi
dual
infect
emphas
asymptomat
infect
respiratori
tract
virus
describ
uncommon
falsey
et
al
kumar
et
al
well
common
peltola
et
al
zalm
et
al
import
low
viral
load
detect
therefor
often
unclear
correl
clinic
diagnosi
conclus
mlpa
assay
greater
sensit
easier
interpret
greater
success
rate
dpo
particular
dpo
combin
experion
dpo
need
less
handson
time
mlpa
howev
assay
rapid
sensit
viral
cultur
good
altern
realtim
rtpcr
